Individualizing the Management of Primary Immunodeficiency Disorders: Considerations in the Selection of Intravenous Immunoglobulin or Subcutaneous Immunoglobulin

Program Description

Primary immunodeficiency disorders (PIDDs) refer to a large group of varying genetic disorders in which one’s immune system endures a developmental or functional deficit. As opposed to secondary immunodeficiency disorders wherein disorders result from external factors, PIDDs occur through genetic errors encoding for immunity. PIDDs have a wide range of effects, commonly resulting in susceptibility to infections, but also may result in a variety of other comorbidities of varying intensity and severity. Diagnosis and treatment of PIDDs and associated conditions proves challenging, as PIDDs are so widely variable. Immunoglobulin replacement, the strongest form of treatment, may be administered intravenously or subcutaneously depending on the severity of protection needed. Choosing between products and dosing for each also proves difficult due to varying aspects of patient cases. Pharmacists should have a strong understanding of PIDDs as well as the various treatment methods for them. This activity will provide pharmacists with the content to better understand PIDDs, including the development and disease process, treatment methods and management, comparing intravenous and subcutaneous immunoglobulin, and the role pharmacists have in the multidisciplinary approach to PIDDs.

Target audience: Health-system and specialty pharmacists

Type of activity: Application
Release date: October 1, 2022
Expiration date: October 1, 2023

Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Determine the etiology, pathophysiology, incidence, types, clinical presentation, and other related complications associated with primary immunodeficiency disorders (PIDDs)
• Explain the standard therapies used for the treatment and management of PIDDs
• Compare intravenous versus subcutaneous immunoglobulin and patient factors to consider in the selection of these agents
• Identify the role of the pharmacist in making clinical recommendations for the treatment and management of PIDDs, in educating patients and caregivers about intravenous and subcutaneous immunoglobulin products, and in monitoring patients for adherence and potential adverse effects

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-22-436-H01-P. The activity is available for CE credit through October 1, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Kyle D. Hackett, PharmD, BCPS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms